Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Thrombosis 1Squamous Cell Carcinoma of Head and Neck 1Sexuality 1Sexual Dysfunction, Physiological 1Salivary Gland Neoplasms 1Radiation Injuries 1Protein Metabolism 1Pain 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Mucositis 1Malnutrition 1Hemorrhage 1Glioblastoma 1Erectile Dysfunction 1Disease 1Diabetes Insipidus 1

Interventions

Sildenafil Citrate 2udenafil 1methyl 3-mercaptopropionimidate 1bicalutamide 1alpha-Tocopherol 1Vitamin E 1Tamoxifen 1Tadalafil 1Tacrolimus 1Restraint, Physical 1Psychiatric Rehabilitation 1Preservation, Biological 1Pentoxifylline 1Menogaril 1Long-Term Synaptic Depression 1Intraoperative Neurophysiological Monitoring 1GPI 1485 1Exercise 1Erythropoietin 1Early Intervention, Educational 1Dutasteride 1Cell- and Tissue-Based Therapy 1Atorvastatin 1Arginine 1ArginMax 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Erectile Dysfunction × Arginine × Clear all
NCT01105130 2021-09-28

L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors

Wake Forest University Health Sciences

Phase 2 Completed
140 enrolled 13 charts
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms, Radiation Injuries

Data powered by HemOnc (CC BY 4.0) Colophon âš¡